New breathing support could save tiny lungs

NCT ID NCT07377955

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two types of high-frequency ventilators for premature babies born before 32 weeks who have breathing problems. The new mode, HFOV-VG, aims to deliver more stable breaths to reduce lung injury. Researchers will see if it lowers the chance of severe chronic lung disease or death compared to standard high-frequency ventilation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

High-frequency oscillatory ventilation with volume guarantee (HFOV-VG) device

What this could lead to

If successful, this could offer a safer breathing support method for premature infants, reducing severe lung disease and death.

What could go wrong

This trial hasn't started yet, and it's a single-center study. The new ventilator mode may not prove better than standard care, and results may not apply to all hospitals.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRONCHOPULMONARY DYSPLASIA (BPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult acute respiratory distress syndrome bronchopulmonary dysplasia Hyaline Membrane Disease respiratory distress syndrome in premature infants

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••